 | | Vol. 11.49 – 15 December, 2020 |
| |
|
|
| The authors showed that ATP levels were markedly increased in the bone marrow niches of mice with acute myeloid leukemia, and leukemia-initiating cells preferred to localize to the endosteal niche with relatively high ATP levels, as indicated by a sensitive ATP indicator.
[Journal of Clinical Investigation] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Scientists demonstrated that the inv(16)/KITD816Y AML mouse model exhibited constitutive activation of PI3K/AKT signaling, which was enhanced by chemotherapy-induced DNA damage through DNA-PK-dependent AKT phosphorylation.
[Leukemia] |
|
|
|
| Investigators unveiled that deletion of Nupr1, a gene preferentially expressed in hematopoietic stem cells (HSCs), activated the quiescence HSCs under homeostatic status, which conferred engraftment competitive advantage on HSCs without compromising their stemness and multi-lineage differentiation abilities in serial transplantation settings.
[Haematologica] |
|
|
|
| The authors combined single-cell profiling with machine learning and in vivo functional studies to explore how hematopoietic stem cell divisions patterns evolve with age.
[Cell Systems] |
|
|
|
| Researchers showed that pervasive and dynamic alternative splicing takes place during hematopoietic development of human pluripotent stem cells. They identified a splicing factor switch that occurs during the differentiation of mesodermal cells to endothelial progenitor cells.
[EMBO Reports] |
|
|
|
| The authors developed a scalable suspension agitation culture platform for differentiating human induced pluripotent stem cell-microcarrier aggregates into functional red blood cells and have demonstrated scalability of the process starting with six well plates and finally demonstrating in 500 mL spinner flasks.
[Stem Cell Reports] |
| |
|
|
| The Phase II HORIZON trial evaluated the efficacy of melflufen plus dexamethasone in relapsed and refractory multiple myeloma, a population with an important unmet medical need.
[Journal of Clinical Oncology] |
|
|
|
| Scientists retrospectively compared outcomes of a large series of adult patients with APL in CR2 receiving alloHSCT or autoHSCT reported to the European Society for Blood and Marrow Transplantation from January 2004 to December 2018.
[Bone Marrow Transplantation] |
|
|
|
| Researchers report the outcome of 34 patients with Fanconi anemia inside a collaborative multicenter national study based on recommendations of Spanish Working Group for Bone Marrow Transplantation in Children between 2009 and 2016.
[Bone Marrow Transplantation] |
|
|
|
|
| The authors review the most recent advances in hematopoietic stem and progenitor cell (HSPC) gene therapy and discuss emerging strategies for using HSPC gene therapy for a range of diseases.
[Nature Reviews Genetics] |
|
|
|
|
| Graphite Bio announced that the FDA has cleared its investigational new drug application (IND) for the experimental gene editing therapy GPH101 to initiate a Phase I/II clinical trial in patients with severe sickle cell disease.
[Graphite Bio] |
|
|
|
|
| January 25 – 28, 2021
Virtual |
|
|
|
|
|
| | NIH National Cancer Institute – Bethesda, Maryland, United States |
|
|
|
| | Rubius Therapeutics – Cambridge, Massachusetts, United States |
|
|
|
| | St. Jude Children’s Research Hospital – Memphis, Tennessee, United States |
|
|
|
| | Stanford University – Stanford, California, United States |
|
|
|
| | New York Blood Center – New York, New York, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
